Royalty Pharma PLC (RPRX) News

Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...

Royalty Pharma Declares Third Quarter 2024 Dividend

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is...

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has...

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 8-K - Current report

Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable...

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology...